Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2001

View Archived Issues

ET antagonists may have therapeutic role in diabetic erectile dysfunction

Abarelix depot shows good results in phase III prostate cancer studies

Bayer's new PDE5 inhibitor improves ED over 12 weeks of therapy

MVAC improves life expectancy in bladder cancer when administered prior to cystectomy

Thalomid/Xeloda combination to be evaluated for treatment of colorectal cancer

Roche and Vernalis identify lead candidate for treatment of obesity

Health Canada approves Rapamune for immunosuppression following renal transplantation

Animal studies demonstrate penile erection-enhancing effects of systemic and intranasal PT-141

Celltech launches Metadate CD for ADHD in U.S.

Joint venture focused on treatment of pain established by CeNeS and Elan

Successful gene transfer obtained following repeated doses of aerosolized tgAAVCF in primates

ZymoGenetics and BioMimetic establish agreement for rhPDGF clinical development

Intratumoral RPR/INGN-201 not associated with biosafety concerns in phase II trial

HGS cleared to proceed with phase I trial of Albutropin for treatment of GH deficiency

Avigen receives FDA approval to begin second trial of Coagulin-B for hemophilia B

INGN-241: preclinical findings reported at American Society of Gene Therapy meeting

Lilly's Zyprexa approved for treatment of schizophrenia in Japan

Miravant to commence phase I trials of new topical PhotoPoint drug for plaque psoriasis

Use of radolmidine for preventing hypotension and shock

Salix reports results of second phase III trial of rifaximin

Antiapoptotic compounds from ARS act on Bax and cytochrome c

Bicyclic amino acids mimic effects of gabapentin, may be useful for neuropathological conditions

Immune Response's phase II trial of Remune fails to meet primary endpoint

GnRH antagonists useful for sex hormone-related disorders claimed by Neurocrine Biosciences

Antiasthmatic effects of YM-976 due mainly to antiinflammatory activity

Tricyclic HIV RT inhibitors prepared at DuPont

Three patents issued to Merck for new antibacterial DNA polymerase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...